Pfizer booster dose offers exceptionally high levels of protection against Covid and all variants, study shows

Risk of symptomatic infection is reduced by 95.6 per cent in people who receive a third dose, compared to those who are vaccinated with two

Samuel Lovett
Science Correspondent
Thursday 21 October 2021 20:31
Comments

A booster dose of the Pfizer-BioNTech vaccine offers exceptionally high levels of protection against coronavirus, including the Delta variant, new trial data shows.

Pfizer said its trial of 10,000 people found that the risk of symptomatic infection was reduced by 95.6 per cent in people who received a third dose, compared to those who were vaccinated with two.

“Based on these findings we believe that, in addition to broad global access to vaccines for everyone, booster vaccinations could play an important role in sustaining pandemic containment and a return to normality,” said Ugur Sahin, head of BioNTech.

Participants in the study were given a booster jab or a placebo 11 months on average after receiving their second dose.

Pfizer said only five cases of Covid-19 were reported among the booster cohort, compared to 109 in the placebo group.

The median age of the participants was 53 years, with 55.5 per cent of participants being between 16 and 55 years and 23.3 per cent being 65 years or older.

The trial took place during a period when the Delta variant was prevalent, proving that the booster jab is effective against this form of the virus.

Pfizer and BioNTech said the effectiveness of the vaccine was “consistent” across age, sex, race, ethnicity, and those with underlying health conditions. They also said that the administration of a third dose was safe.

The two companies said they would submit detailed results of the trial to the Food and Drug Administration in the US, the European Medicines Agency, and other regulatory agencies as soon as possible.

US, EU and UK regulators have already authorised a third dose of Covid-19 vaccines by Pfizer-BioNTech and Moderna for patients with compromised immune systems, who are likely to have weaker protection from the two-dose regimens.

Research has shown that the effectiveness of the Pfizer vaccine against symptomatic disease falls from 96 per cent to 84 per cent four months after a second dose.

Amid fears of waning immunity – though the vaccine, along with other authorised jabs, continues to offer high levels of protection against hospitalisation and death – a number of countries have already pushed ahead with national booster programmes for elderly and vulnerable groups.

The move has proved controversial and divisive, with billions of people across the world yet to receive a first vaccine dose.

In the UK, the government has urged the public to come forward for a booster jab when invited to do so.

With cases back on the rise in Britain and the NHS facing ever-mounting pressure, health secretary Sajid Javid warned people that unless they “do their bit” by taking up the offer of vaccines and booster jabs, they could lose the freedoms they have enjoyed since the lifting of all restrictions in July.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Please enter a valid email
Please enter a valid email
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Please enter your first name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
Please enter your last name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
You must be over 18 years old to register
You must be over 18 years old to register
Opt-out-policy
You can opt-out at any time by signing in to your account to manage your preferences. Each email has a link to unsubscribe.

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Join our new commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged in